London-based LabGenius, which uses AI and “robotic automation” for protein drug discovery, raises $10M Series A led by Lux Capital and Obvious Ventures
LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.
Context & Ripple Effects
LabGenius's $10M Series A lands in a London AI-drug-discovery cluster that was already attracting outsized checks: a year earlier, BenevolentAI raised $115M at a $2.1B post-money valuation out of the same city. Where BenevolentAI pitched broad AI-for-drugs ambition, LabGenius is betting on the narrower pairing of machine learning with robotic automation for protein therapeutics.
The round reads differently in hindsight: five years on, LabGenius closed a £35M Series B led by Merck's venture arm M Ventures, shifting from generalist backers (Lux Capital, Obvious Ventures) to a strategic pharma investor once the antibody-discovery platform matured.
First-order effects
- Lux Capital and Obvious Ventures give LabGenius the capital to build out its AI-plus-robotics protein discovery loop, while positioning it as the focused protein-therapeutics counterpart to the far larger, broader-scope BenevolentAI in its own city.
Second-order effects
- Pharma corporate VCs become the natural next layer of the cap table — Merck's M Ventures eventually leading LabGenius's Series B shows how strategic money follows once an automated discovery platform proves itself.
- Lab automation vendors gain demand from newly funded discovery startups; Artificial's $21.5M round for laboratory R&D automation software two years later signals that the robotics side of these platforms is becoming a fundable market of its own.
Third-order effects
- If the pattern holds, AI-driven drug discovery stratifies into a repeatable funding ladder — generalist seed/Series A money into narrow platform bets, then pharma strategics at Series B and beyond — with London sustaining a dense pipeline of such startups, from BenevolentAI through Latent Labs' $50M emergence to Excelsior Sciences' $70M small-molecule round.
The trend: AI-native drug discovery is maturing into its own institutional asset class, with London as Europe's densest cluster and pharma corporate VCs progressively displacing generalists as platforms de-risk.